Funding for this research was provided by:
Ampio Pharmaceuticals, Inc (NA)
Received: 30 April 2018
Accepted: 21 May 2018
First Online: 4 June 2018
Ethics approval and consent to participate
: The study was approved from the Integreview Institutional Review Board with waiver of documentation of informed consent (AP-007-B).
: Dr. Schwappach reports consulting fees paid to his institution. Mrs. Salottolo reports personal fees from Ampio Pharmaceuticals, Inc., and own stocks and stock options in the company. Dr. Bar-Or is an employee of Ampion Pharmaceuticals, Inc. and serves as the chief Scientific officer of Ampio Pharmaceuticals and own stocks and stock options in the company. In addition, Dr. Bar-Or has more than 120 issued patents and 80 pending. Mr. Schultz has no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.